TP53 and acute myeloid leukemia: The most promising efficacy of the triplet therapy was in newly diagnosed high-risk patients, notably ND TP53–wt (ORR: 63%, mOS 18.9m) and TP53 mutant AML (ORR 69%, mOS 12.9m).